Aft Pharmaceuticals Foreign Exempt NZX Targets Phase III for Injectable Iron
FDA clears AFT’s injectable iron project to advance into Phase III trials
The US Food and Drug Administration (FDA) has reviewed AFT Pharmaceuticals’ Investigational New Drug (IND) application for its injectable iron research and development project and allowed it to proceed to a Phase III clinical trial.
The milestone was detailed in a presentation delivered by Managing Director Dr Hartley Atkinson to the 2026 Bio International Convention in San Diego, California, on 23 June 2026.
AFT Pharmaceuticals (NZX: AFT; ASX: AFP) and its development partner Hyloris Pharmaceuticals plan a global confirmatory study involving 1,366 patients. The project targets an addressable market estimated at US$7.41 billion, marking a regulatory gate cleared on an asset positioned within a multi-billion-dollar therapeutic category.
When big ASX news breaks, our subscribers know first
Inside the Phase III confirmatory study
The presentation outlined a large global confirmatory study designed to enrol 1,366 patients across multiple geographies. AFT will undertake the trial alongside Hyloris Pharmaceuticals, which is named as its development partner on the project.
The study is planned across the following regions and countries:
-
New Zealand
-
China
-
India
-
Japan
-
Armenia
-
Europe
-
United States
The broad multi-geography design supports global market access ambitions across multiple regulatory jurisdictions, an approach that can streamline the path to commercialisation should the trial succeed.
| Detail | Figure | Significance |
|---|---|---|
| IND status | Allowed to proceed (FDA) | Clears path to Phase III |
| Trial size | 1,366 patients | Large confirmatory dataset |
| Geographies | 7 regions/countries | Global market readiness |
| Addressable market | US$7.41 billion | Scale of commercial opportunity |
| Development partner | Hyloris Pharmaceuticals | Shared development pathway |
Why intravenous iron matters — and why this milestone counts
An Investigational New Drug (IND) application is a formal submission to the FDA seeking permission to test a new medicine in humans. When the FDA “allows the IND to proceed,” it has cleared the company to begin human trials. This is a regulatory step to start testing, distinct from final marketing approval that would permit the product to be sold.
Clearing the IND removes a key regulatory hurdle and moves the project toward a market that industry estimates place at significant scale.
The market opportunity
The project targets an addressable market estimated at US$7.41 billion. This figure is an industry estimate for the intravenous iron drugs market to around 2033, sourced from biospace, and is not a revenue forecast issued by AFT.
What it means for AFT investors
AFT Pharmaceuticals is described as a growing New Zealand based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of products across over the counter (OTC), prescription and hospital channels. Its markets include Australia, New Zealand, Singapore, Malaysia, Hong Kong, the USA, Canada, the EU ex Ireland and UK, with out-licensing arrangements extending to over 125 countries.
The injectable iron project sits within AFT’s portfolio of proprietary and in-licensed products. Progressing the asset into Phase III adds a late-stage, high-value candidate to that development pipeline.
AFT’s broader development pipeline spans eight patented products targeting combined markets exceeding US$18 billion, with the injectable iron project among the late-stage assets underpinning the company’s FY27 revenue target of $300 million or more.
For investors, the FDA’s clearance to proceed represents tangible progress on a project addressing a large therapeutic market.
Presentation context
In his presentation to the 2026 Bio International Convention, Managing Director Dr Hartley Atkinson outlined that the FDA has allowed AFT’s IND application for the injectable iron project to proceed, clearing the way for the planned global confirmatory study with Hyloris Pharmaceuticals.
The next major ASX story will hit our subscribers first
The road ahead
The next step is for AFT and Hyloris Pharmaceuticals to undertake the global confirmatory Phase III study across the planned geographies of New Zealand, China, India, Japan, Armenia, Europe and the United States.
The announcement does not disclose a trial start date, completion timeline, study cost or the funding split between AFT and Hyloris. As the project advances through this late-stage trial, progression will remain a point of interest for investors tracking AFT’s broader development pipeline.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to make sure the next major clinical milestone lands in your inbox the moment it breaks.